News From the Field

Researchers create biomaterial that delivers both a powerful drug and gene silencers


August 9, 2017

This material is available primarily for archival purposes. Telephone numbers or other contact information may be out of date; please see current contact information at media contacts.

Clinicians today have a huge arsenal of drugs at their disposal for treating cancers. But many chemotherapeutic agents pose stubborn challenges: They cause serious side effects, some cancers develop resistance, and many chemotherapies demonstrate low bio-availability. A potential solution lies in the synergistic combination of a chemotherapeutic drug with engineered genetic material.Full Story

Source
New York University Tandon School of Engineering

The U.S. National Science Foundation propels the nation forward by advancing fundamental research in all fields of science and engineering. NSF supports research and people by providing facilities, instruments and funding to support their ingenuity and sustain the U.S. as a global leader in research and innovation. With a fiscal year 2023 budget of $9.5 billion, NSF funds reach all 50 states through grants to nearly 2,000 colleges, universities and institutions. Each year, NSF receives more than 40,000 competitive proposals and makes about 11,000 new awards. Those awards include support for cooperative research with industry, Arctic and Antarctic research and operations, and U.S. participation in international scientific efforts.

mail icon Get News Updates by Email 

Connect with us online
NSF website: nsf.gov
NSF News: nsf.gov/news
For News Media: nsf.gov/news/newsroom
Statistics: nsf.gov/statistics/
Awards database: nsf.gov/awardsearch/

Follow us on social
Twitter: twitter.com/NSF
Facebook: facebook.com/US.NSF
Instagram: instagram.com/nsfgov